NASDAQ:NVIV - Invivo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.06 +0.04 (+1.98 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$2.02
Today's Range$2.02 - $2.16
52-Week Range$1.63 - $63.75
Volume318,400 shs
Average Volume179,941 shs
Market Capitalization$3.30 million
P/E Ratio-0.11
Dividend YieldN/A
Beta2.67
Invivo Therapeutics logoInVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Debt-to-Equity Ratio0.03
Current Ratio3.20
Quick Ratio3.20

Price-To-Earnings

Trailing P/E Ratio-0.11
Forward P/E Ratio-0.46
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.37 per share
Price / Book0.28

Profitability

EPS (Most Recent Fiscal Year)($18.50)
Net Income$-26,740,000.00
Net MarginsN/A
Return on Equity-194.69%
Return on Assets-144.68%

Miscellaneous

Employees12
Outstanding Shares1,650,000
Market Cap$3.30

Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics's stock reverse split before market open on Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($3.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($3.25) by $0.09. View Invivo Therapeutics' Earnings History.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Invivo Therapeutics.

What is the consensus analysts' recommendation for Invivo Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invivo Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Invivo Therapeutics' key competitors?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the folowing people:
  • Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 60)
  • Mr. Mark D. Perrin, Consultant (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder and Member of Scientific Advisory Board (Age 69)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 69)
  • Mr. Jeffrey Modestino, Principal Financial Officer, Principal Accounting Officer & Treasurer

Has Invivo Therapeutics been receiving favorable news coverage?

News articles about NVIV stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Invivo Therapeutics earned a media sentiment score of 0.22 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.56 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $2.06.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $3.30 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis. Invivo Therapeutics employs 12 workers across the globe.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  169
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.